Skip to main content
. 2022 Mar 2;2(2):100133. doi: 10.1016/j.xops.2022.100133

Figure 4.

Figure 4

Graphs showing specialized chromatic full-field stimulus testing (FST) results of participant P10 at baseline and months 1 through 3 in the untreated control eye and study eye, which received an intravitreal injection of 320 μg sepofarsen. A–D, Full-field stimulus testing threshold changes from the baseline mean are shown for red (A, B) and blue (C, D) stimuli under dark-adapted (DA) and light-adapted (LA) conditions. Maximum treatment (Tx) potential predicted from artificial intelligence evaluation of patient P10’s foveal OCT data are shown for DA FST (A, C). Gray dashed line represents no change from baseline. Symbols and error bars represent mean and ±1 standard deviation. E, F, Interocular difference of mean DA and LA FST thresholds.